SEI Medical Public Co., Ltd.

As of June 30, 2026, SEI Medical Public Co., Ltd. carries a market capitalization of 282.20M, placing it among publicly traded companies globally. Its enterprise value stands at 288.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SEI Medical Public Co., Ltd. has 170.00M shares outstanding.

As of June 30, 2026, SEI Medical Public Co., Ltd. trades at a trailing price-to-earnings ratio of 9.14. The price-to-sales ratio is 0.69, and the price-to-book ratio stands at 0.92.

As of June 30, 2026, SEI Medical Public Co., Ltd. trades at an EV/EBITDA multiple of 5.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 288.66M versus a market cap of 282.20M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SEI Medical Public Co., Ltd. maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.41, indicating elevated leverage, while an interest coverage ratio of 24.23 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SEI Medical Public Co., Ltd. posted a return on equity (ROE) of 10.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.92, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.86 indicates how many times SEI Medical Public Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SEI Medical Public Co., Ltd. recorded 8.18M in income tax expense. That works out to an effective tax rate of 20.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 39.05M, leaving 30.87M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, SEI Medical Public Co., Ltd.'s stock has declined approximately 19.26% over the past 52 weeks. The 50-day moving average sits at 1.84, while the 200-day moving average is 1.95.

Over the twelve months ended June 30, 2026, SEI Medical Public Co., Ltd. generated 411.51M in revenue and converted that into 30.87M in net income, yielding earnings per share of 0.18. EBITDA reached 57.39M, while operating income came in at 39.95M.

As of June 30, 2026, SEI Medical Public Co., Ltd. holds 127.15M in cash and equivalents against 133.60M in total debt, resulting in a net debt position of -671,697.00. Total book value stands at 307.77M, with working capital of 206.97M providing operational flexibility.

SEI Medical Public Co., Ltd. produced -27.99M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -38.72M in capital expenditures, free cash flow totaled -66.71M - equivalent to -0.39 per share.

Over the twelve months ended June 30, 2026, SEI Medical Public Co., Ltd. posted a gross margin of 37.01, reflecting its pricing power and cost economics. The operating margin of 9.71 and net profit margin of 7.50 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SEI Medical Public Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -23.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.32, meaning SEI Medical Public Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, SEI Medical Public Co., Ltd. has an Altman Z-Score of 2.54, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.